San Diego, CA-based biotech Ignyta Inc. has revealed interim Phase II results for its lead product, the targeted anticancer entrectinib, that it believes show the drug to have best-in-class potential in non-small cell lung cancer (NSCLC).
Entrectinib is a potent and selective small molecule tyrosine kinase inhibitor of the TRK (tropomyosin receptor kinase) family of tyrosine...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)